
Loading, please wait...

Loading, please wait...

The Union Health Ministry has officially launched a nationwide HPV vaccination campaign to combat the high burden of cervical cancer in India. Consequently, the government aims to vaccinate approximately 1.15 crore girls aged 14 years every year across all states. This initiative aligns with the 'Swastha Nari' vision, focusing on protection and equity in women's healthcare. Therefore, the vaccine will be available free of cost at various government health facilities, including Ayushman Arogya Mandirs and district hospitals.
During the initial three-month mission mode phase, eligible girls can receive the vaccine daily at designated centers. Furthermore, the program will transition into routine immunization schedules after this intensive period. It is important to note that vaccination is voluntary. Thus, healthcare providers must obtain informed consent from parents or guardians before administration. Additionally, every session will have supervision from trained medical officers to ensure safety.
The campaign utilizes the Gardasil 4 vaccine, which is a quadrivalent option protecting against HPV types 6, 11, 16, and 18. Specifically, types 16 and 18 cause over 80% of cervical cancer cases in India. Clinical evidence suggests that these vaccines are highly effective. For instance, studies show 93-100% effectiveness in preventing cervical cancer caused by these specific types. Moreover, India has adopted a single-dose schedule for this rollout. This decision follows recommendations from the World Health Organization and India's National Technical Advisory Group on Immunisation.
Scientific data confirms that a single dose provides protection comparable to multi-dose schedules for girls aged 9-20. Because of this, more than 90 countries have already moved to single-dose protocols to improve coverage and affordability. India now joins over 160 nations that have integrated HPV vaccination into their national programs. Meanwhile, the government has secured supplies through a transparent mechanism with GAVI to ensure uninterrupted availability across the country.
Q1: Who is the primary target group for this vaccination drive?
The campaign primarily targets girls aged 14 years across all states and Union territories in India.
Q2: Is the HPV vaccine being provided as a single dose or double dose?
India is implementing a single-dose schedule of the Gardasil 4 vaccine, following WHO and NTAGI recommendations for this age group.
Q3: Where can eligible girls receive the vaccine?
Vaccines are available for free at government medical colleges, district hospitals, community health centers, and Ayushman Arogya Mandirs.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The Indian government has launched a nationwide HPV vaccination drive targeting 1.15 crore girls aged 14 annually to reduce cervical cancer incidence....
7 months ago

Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today

A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today